Compare Quest Diagnostics Inc (DGX) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs OneSpan Inc — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while OneSpan Inc trades at $15.67 (market cap $574.63M). The key difference: Quest Diagnostics Inc is far larger — about 39.7× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.35%). Which is the better fit depends on your goals.
| DGX | OSPN | |
|---|---|---|
Market Cap | $22.80B | $574.63M |
Sector | Health | Technology |
52-Week High | $216.02 | $16.32 |
52-Week Low | $166.42 | $10.15 |
Enterprise Value | $28.82B | $532.83M |
Dividend Yield | 1.67% | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
OneSpan (OSPN) trades at $15.09, down 0.53% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company demonstrates strong profitability with a net income margin of 28.47% and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and the upcoming Q2 2026 earnings release on August 4, 2026.
The outlook remains positive given consistent earnings beats and a 66.7% analyst buy rating, though the consensus price target of $13.50 suggests limited upside. Risks include negative net cash flow trends and potential margin compression, but strong ROE of 27.81% supports shareholder value. The stock presents a value opportunity with a P/E of 8.56, but investors should monitor execution against future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
